AstraZeneca US live at 2017 ASCO Annual Meeting


This week, AstraZeneca, along with its global biologics research and development arm, MedImmune, will demonstrate how we are rapidly delivering on our science-led strategy for transformational cancer drug development at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, June 2-6, with 100 company-sponsored and supported abstracts, including five Best-of-ASCO presentations, 11 oral presentations and eight poster discussions.

We are committed to advancing the science of oncology as one of our five Growth Platforms – with a focus on lung, ovarian, breast and blood cancers, and the goal of redefining cancer treatments to one day eliminate cancer as a cause of death.


Press Releases

AstraZeneca presents TAGRISSO® (osimertinib) data in patients with EGFR T790M-mutation positive lung cancer and central nervous system metastases

June 6, 2017


LYNPARZA™ (olaparib) significantly reduces the risk of disease worsening or death in patients with BRCA-mutated metastatic breast cancer

June 4, 2017


AstraZeneca delivers new data on expanding portfolio of cancer medicines at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

May 26, 2017

Personalizing Lung Cancer: Why Testing Matters